15 September 2022 
EMA/690314/2022  
Human Medicines Evaluation Division 
Statement indicating compliance with the agreed 
completed paediatric investigation plan 
Medicinal product  
Repathat/ evolocumab 
See Annex A  
Pharmaceutical form(s): 
See Annex A 
Strength(s): 
Route(s) of administration: 
See Annex A 
Packaging and package size(s):  See Annex A 
See Annex A 
Number(s) in the Community 
Register of Medicinal Products: 
Marketing authorisation holder (MAH): 
Name and address of the MAH:  Amgen Europe B.V. 
Minervum 7061 
4817 ZK Breda 
NETHERLANDS 
Procedure  
Procedure number: 
EMEA/H/C/003766/IB/0059 
Further to the compliance check performed under Article 23 of Regulation (EC) No 1901/2006, and in 
accordance with Article 28(3) and Article 45(3) of the said Regulation it is concluded that: 
-the development of this product has complied with all measures in the agreed paediatric investigation 
plan P/0105/2018 .All studies in the agreed paediatric investigation plan P/0105/2018 were conducted 
after the entry into force of that Regulation, 
-the Summary of Product Characteristics adopted by CHMP already reflected the results of studies 
conducted in compliance with this agreed paediatric investigation plan. 
In accordance with Article 23a of Regulation (EC) No 1234/2008, this statement indicating 
compliance with the agreed completed paediatric investigation plan P/0105/2018 is included in the 
technical dossier. 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union   
© European Medicines Agency, 2023. Reproduction is authorised provided the source is acknowledged. 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
